Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial

Autor: Le Gars, Mathieu, Sadoff, Jerald, Cárdenas, Vicky, Heerwegh, Dirk, Tesfaye, Fisseha, Roey, Griet Van, Spicer, Colleen, Matias, Samantha Santoro, Crayne, Olivia, Kamphuis, Tobias, Struyf, Frank, Schuitemaker, Hanneke, Douoguih, Macaya
Zdroj: In Vaccine 25 July 2024 42(19):3938-3952
Databáze: ScienceDirect
Externí odkaz: